Health officials in England have identified a newly evolved mpox variant after a recent traveller from Asia tested positive for the virus. Genome sequencing confirmed that the infection is a recombinant strain, containing genetic material from both clade 1, known for causing more severe illness, and clade 2, the strain responsible for the 2022 global outbreak.
The UK Health Security Agency announced that more analysis is underway to determine whether the new variant poses an increased risk. While most mpox cases remain mild, experts warn that the virus continues to evolve, making genomic surveillance and vaccination for eligible groups essential.
Mpox, formerly known as monkeypox, spreads through close physical contact with infected lesions or materials, and can also be passed on via respiratory droplets. Symptoms can take up to three weeks to appear and typically include fever, muscle pain, fatigue, followed by a rash.
The emergence of a recombinant strain is not unexpected as both clades currently circulate globally. However, it highlights the potential for further evolution and the need for ongoing monitoring. The WHO recorded almost 48,000 mpox cases worldwide in 2025, along with over 200 deaths.
Vaccination is recommended for people at higher risk, including those with multiple sexual partners or those who attend sex-on-premises venues. Researchers say identifying more cases of this strain will be key to understanding whether it poses greater or lesser danger than previous ones.
Experts stress that staying informed and continuing prevention efforts remain important as the situation develops.
